 |
|
|
| |
Ledipasvir/Sofosbuvir ± Ribavirin for 12 or 24 Weeks Is Safe and Effective in Children 6-11 years old with Chronic Hepatitis C Infection
|
| |
| |
Jules Levin
EASL 2017 April 19-22 Amsterdam Netherlands
Karen F. Murray1, William Balistreri2, Sanjay Bansal3, Suzanne Whitworth4, Helen Evans5,
Regino P. Gonzalez-Peralta6,Jessica Wen7, Benedetta Massetto8, Kathryn Kersey8, Jiang Shao8, Kim Garrison8, Evguenia Svarovskaia8, Diana M.Brainard8, Ronen Arnon9, Lynette Gillis10, Maureen M. Jonas11, Chuan-Hao Lin12, Michael R. Narkewicz13, Kathleen Schwarz14, Philip Rosenthal15
1Seattle Children's Hospital, Seattle, Washington, USA; 2Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; 3Kings College Hospital, London, United Kingdom; 4Cook Children's Health Care System, Fort Worth, Texas, USA; 5Auckland Clinical Studies, Auckland, New Zealand; 6University of Florida, Gainesville, USA; 7The Children's Hospital of Philadelphia, Pennsylvania, USA; 8Gilead Sciences, Inc., Foster City, California, USA; 9Mount Sinai Medical Center, New York, New York, USA; 10Monroe Carell, Jr. Children's Hospital, Vanderbilt, Nashvilee, Tennessee, USA; 11Boston Children's Hospital, Boston, Massachusetts, USA; 12Children's Hospital Los Angeles, California; 13University of Colorado School of Medicine and Children's Hospital of Colorado, Aurora, USA; 14The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 15University of San Francisco, California, USA.
|
| |
|
|
|
|
|
